Bayer Signs an Exclusive License Agreement with Kyoto University for Pulmonary Disorders

Bayer Signs an Exclusive License Agreement with Kyoto University for Pulmonary Disorders

Shots:

  • Bayer and Kyoto University collaborate to jointly conduct clinical trials for identifying targets in lung diseases. Bayer will have an exclusive option to license the developed product in the trial
  • The focus of the agreement is to discover targets and develop treatments, with combined techniques of the company in pulmonary disorders including idiopathic pulmonary fibrosis (IPF)
  • In 2014, Bayer and Kyoto University’s Office of Society-Academia Collaboration for Innovation (KU-SACI) collaborated to jointly explore candidates for certain research projects in areas cardiology & oncology including hematology, gynecology, and ophthalmology

Click here to read full press release/ article | Ref: Bayer | Image: Bayer